EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Exploring the Anticancer and Anti-inflammatory Activities of Ferruginol in MCF-7 Breast Cancer Cells

Thamaraiselvan Rengarajan, Sundararaj Keerthiga, Sivakumar Duraikannu, Velu Periyannan

Cancer Plus · 2019-11-09 · 1 (4) · 1

DOI: 10.18063/cp.v1i4.255 ↗
AbstractBibliografische Angaben

Abstract

Breast cancer is one of the most prevalent cancers in women, and it has the highest mortality and morbidity worldwide. Breast cancer can be treated by hormone therapies, radiotherapy, surgery, and chemotherapy, but it is often associated with multiple deleterious effects. In this present work, we explored the anti-inflammatory and anticancer effects of ferruginol in MCF-7 cells. The effects of ferruginol on the cell growth and viability of MCF-7 cells were determined by the MTT assay and apoptotic markers. In addition, mitochondrial membrane potential (MMP) status as well as the levels of intracellular reactive oxygen species (ROS), superoxide dismutase, catalase, glutathione, thiobarbituric acid reactive substances (TBARS), caspase-3 and caspase-9 in the ferruginol-treated MCF-7 cells were examined. In addition, expression of inflammation-related proteins such as tumor necrosis factor-alpha (TNF-α), interleukin-6 (IL-6), nuclear factor kappa B (NF-κB) p65, inducible nitric oxide synthase (iNOS), and cyclooxygenase-2 (COX-2) was determined using Western blotting. Our findings showed that ferruginol activated the apoptosis in MCF-7 through a reduction of cell viability. Furthermore, ferruginol-treated MCF-7 cells also showed a decrease of MMP, an increase of ROS, TBARS, caspase-3 and caspase-9, as well as a reduction of antioxidant proteins. Ferruginol treatment is also downregulated the expression of inflammatory modulators such as TNF-α, iNOS, COX-2, NF-κB p65, and IL-6 in MCF-7 cells. In conclusion, ferruginol inhibits the inflammation and activated apoptosis by modulating the expression of inflammatory and apoptotic markers. Therefore, ferruginol may serve as a potential curative agent for breast cancer

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →